Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis

Deregulated expression of heat shock proteins (HSPs) encoding genes is frequent in multiple myeloma. HSPs, which are molecular chaperones involved in protein homeostasis pathways, have emerged recently as promising therapeutic targets. Using human myeloma cell lines and primary myeloma cells belongi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bustany, Sophie, Cahu, Julie, Descamps, Géraldine, Pellat-Deceunynck, Catherine, Sola, Brigitte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435646/
https://www.ncbi.nlm.nih.gov/pubmed/25898974
http://dx.doi.org/10.1186/s13045-015-0135-3
_version_ 1782371951026634752
author Bustany, Sophie
Cahu, Julie
Descamps, Géraldine
Pellat-Deceunynck, Catherine
Sola, Brigitte
author_facet Bustany, Sophie
Cahu, Julie
Descamps, Géraldine
Pellat-Deceunynck, Catherine
Sola, Brigitte
author_sort Bustany, Sophie
collection PubMed
description Deregulated expression of heat shock proteins (HSPs) encoding genes is frequent in multiple myeloma. HSPs, which are molecular chaperones involved in protein homeostasis pathways, have emerged recently as promising therapeutic targets. Using human myeloma cell lines and primary myeloma cells belonging to various molecular groups, we tested the efficacy of HSP90, HSP70, and heat shock factor 1 (HSF1) inhibitors alone or associated with current antimyeloma drugs. We report here that KNK-437 (an inhibitor of HSF1) and bortezomib have additive effects on apoptosis induction in cells belonging to groups with bad prognosis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-015-0135-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4435646
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44356462015-05-19 Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis Bustany, Sophie Cahu, Julie Descamps, Géraldine Pellat-Deceunynck, Catherine Sola, Brigitte J Hematol Oncol Letter to the Editor Deregulated expression of heat shock proteins (HSPs) encoding genes is frequent in multiple myeloma. HSPs, which are molecular chaperones involved in protein homeostasis pathways, have emerged recently as promising therapeutic targets. Using human myeloma cell lines and primary myeloma cells belonging to various molecular groups, we tested the efficacy of HSP90, HSP70, and heat shock factor 1 (HSF1) inhibitors alone or associated with current antimyeloma drugs. We report here that KNK-437 (an inhibitor of HSF1) and bortezomib have additive effects on apoptosis induction in cells belonging to groups with bad prognosis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-015-0135-3) contains supplementary material, which is available to authorized users. BioMed Central 2015-04-23 /pmc/articles/PMC4435646/ /pubmed/25898974 http://dx.doi.org/10.1186/s13045-015-0135-3 Text en © Bustany et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Letter to the Editor
Bustany, Sophie
Cahu, Julie
Descamps, Géraldine
Pellat-Deceunynck, Catherine
Sola, Brigitte
Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis
title Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis
title_full Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis
title_fullStr Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis
title_full_unstemmed Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis
title_short Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis
title_sort heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435646/
https://www.ncbi.nlm.nih.gov/pubmed/25898974
http://dx.doi.org/10.1186/s13045-015-0135-3
work_keys_str_mv AT bustanysophie heatshockfactor1isapotenttherapeutictargetforenhancingtheefficacyoftreatmentsformultiplemyelomawithadverseprognosis
AT cahujulie heatshockfactor1isapotenttherapeutictargetforenhancingtheefficacyoftreatmentsformultiplemyelomawithadverseprognosis
AT descampsgeraldine heatshockfactor1isapotenttherapeutictargetforenhancingtheefficacyoftreatmentsformultiplemyelomawithadverseprognosis
AT pellatdeceunynckcatherine heatshockfactor1isapotenttherapeutictargetforenhancingtheefficacyoftreatmentsformultiplemyelomawithadverseprognosis
AT solabrigitte heatshockfactor1isapotenttherapeutictargetforenhancingtheefficacyoftreatmentsformultiplemyelomawithadverseprognosis

Ejemplares similares